Genentech Avastin Approved For Colorectal Cancer With Five-Month Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
The angiogenesis inhibitor gets full FDA approval Feb. 26. Genentech said it will begin shipping the biologic within three days.